ArticleParasites & vectors2025
Exploratory study on the role of Clonorchis sinensis infection in promoting cholangiocarcinoma progression.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundClonorchiasis, a neglected tropical zoonosis, is caused by chronic infection with Clonorchis sinensis (C. sinensis). This infection can lead to cholangitis, bile duct epithelial hyperplasia, periductal fibrosis, and cholangiocarcinoma (CCA). However, the underlying carcinogenic mechanisms of CCA remain poorly understood, and there is not a well-developed model for C. sinensis CCA.
methodsA C. sinensis-infected Sprague-Dawley rat model, co-treated with N-nitrosodimethylamine, was established. The study comprised four groups: negative control (NC), C. sinensis infection (CS), N-nitrosodimethylamine induction (NDMA), and combined C. sinensis infection and N-nitrosodimethylamine induction (CSNDMA). Pathological damage to the hepatic ducts was evaluated at 10, 17, and 20 weeks after infection. The expression levels of the relevant genes and proteins were detected using quantitative real-time polymerase chain reaction (qPCR) and immunohistochemistry, respectively. In addition, transcriptome sequencing was carried out on hepatic tissues infected for 20 weeks.
resultsHistopathological analysis using hematoxylin and eosin (H&E) and Masson staining revealed bile duct dilation, inflammatory infiltration, and collagen deposition in the liver tissue of both CS and CSNDMA groups, with the most severe manifestations observed in the CSNDMA group. The CSNDMA group exhibited the earliest onset of CCA, occurring at 10 weeks post infection, with an overall incidence of 63%, peaking at 71% by 20 weeks. The CS group showed a 37% incidence of CCA, while only one case was noted in the NDMA group at 20 weeks. Quantitative PCR demonstrated that C. sinensis infection induced upregulation of tumor-related markers in the liver, including CK19, PCNA, TP53, ITGB1, and MMP2, particularly when co-exposed to N-nitrosodimethylamine. Immunohistochemistry detected the significant overexpression of CK19, CK7, and PCNA along bile ducts. Transcriptome sequencing further indicated that C. sinensis significantly affected circadian rhythm and metabolic reprogramming in the liver, enriching pathways related to cancer, inflammation, and metabolism, including AMPK, PPAR, mTOR, and FoxO pathways.
conclusionsC. sinensis can effectively promote the pathogenesis of CCA and significantly increase the expression of CCA-related genes (e.g., CK19 and CK7). The inflammation, disrupting circadian rhythms and altering energy metabolism caused by C. sinensis infection, may promote the progression of CCA. This study provides a foundational experimental basis for diagnosing and intervening in C. sinensis-related CCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.